Perfusion is rapidly evolving from a niche manufacturing approach into a strategic advantage, delivering higher productivity, improved process consistency, and enhanced product quality through advances in cell culture, filtration, and real-time automation. And as biomanufacturing milestones evolve, perfusion is emerging as a powerful complement to traditional fed-batch processes for organizations looking to bring next-generation biologics to market.
In a recent article from GEN, Charles Solanke, a Cytovance Senior Scientist of Upstream Process Development, sits down with Mike May, PhD, and shares how perfusion is benefiting from a wave of technological advances that are making the approach more practical and economically attractive for commercial-scale manufacturing.
Read the full article here.